LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Akciju saraksts・10X Genomics Inc (Class A)

10X Genomics Inc (Class A)

Slēgts

SektorsVeselības aprūpe

32.2 5.02

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

29.81

Max

32.28

Galvenie mērījumi
By Trading Economics
Ienākumi	2.8M -13M
Pārdošana	-15M 151M
EPS	0.07
Peļņas marža	-8.93
Darbinieki	1,178
EBITDA	2.5M -17M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	-17.2% downside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 6. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	964M 3.8B
Iepriekšējā atvēršanas cena	27.18
Iepriekšējā slēgšanas cena	32.2

Ziņu noskaņojums

By Acuity

50%

154 / 344 Rangs Healthcare

10X Genomics Inc (Class A) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. jūn. 23:22 UTC

Peļņas

Galvenie tirgus virzītāji

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

2026. g. 3. jūn. 23:09 UTC

Karstas akcijas

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

2026. g. 3. jūn. 20:51 UTC

Peļņas

Costco Reports 15% Sales Growth in May

2026. g. 3. jūn. 20:43 UTC

Peļņas

Broadcom 2Q Revenue Climbs on AI Chip Demand

2026. g. 3. jūn. 23:48 UTC

Tirgus saruna

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

2026. g. 3. jūn. 23:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 3. jūn. 23:35 UTC

Tirgus saruna

Oil Futures Fall on Possible Technical Correction -- Market Talk

2026. g. 3. jūn. 23:15 UTC

Tirgus saruna

Peļņas

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

2026. g. 3. jūn. 22:08 UTC

Karstas akcijas

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

2026. g. 3. jūn. 21:54 UTC

Tirgus saruna

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

2026. g. 3. jūn. 21:18 UTC

Peļņas

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

2026. g. 3. jūn. 21:15 UTC

Peļņas

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

2026. g. 3. jūn. 21:13 UTC

Peļņas

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

2026. g. 3. jūn. 21:13 UTC

Peļņas

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

2026. g. 3. jūn. 21:12 UTC

Peļņas

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

2026. g. 3. jūn. 21:09 UTC

Peļņas

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

2026. g. 3. jūn. 21:03 UTC

Peļņas

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

2026. g. 3. jūn. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. jūn. 20:43 UTC

Peļņas

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

2026. g. 3. jūn. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

2026. g. 3. jūn. 20:37 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

2026. g. 3. jūn. 20:35 UTC

Peļņas

Broadcom Stock Falls Despite Record Results -- Barrons.com

2026. g. 3. jūn. 20:21 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

2026. g. 3. jūn. 20:17 UTC

Peļņas

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

2026. g. 3. jūn. 20:17 UTC

Peļņas

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

2026. g. 3. jūn. 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

2026. g. 3. jūn. 20:15 UTC

Peļņas

Broadcom 2Q Adj EPS $2.44 >AVGO

2026. g. 3. jūn. 20:15 UTC

Peļņas

Broadcom 2Q EPS $1.91 >AVGO

2026. g. 3. jūn. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 3. jūn. 20:15 UTC

Peļņas

Broadcom 2Q Rev $22.19B >AVGO

Salīdzinājums

Cenas izmaiņa

10X Genomics Inc (Class A) Prognoze

Cenas mērķis

By TipRanks

-17.2% uz leju

Prognoze 12 mēnešiem

Vidējais 24.5 USD -17.2%

Augstākais 32 USD

Zemākais 20 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi 10X Genomics Inc (Class A) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam 10X Genomics Inc (Class A) — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

154 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.